Dow Jones
38.121,18 -320,36 (-0,83%) Nasdaq
16.808,70 -111,88 (-0,66%) Nikkei 225
38.054,13 -502,74 (-1,30%) EUR/USD
1,0841 +0,0034 (+0,31%) Bitcoin EUR
63.945,12 +1.830,50 (+2,95%) CMC Crypto 200
1.449,81 -6,06 (-0,42%)
Bolt Biotherapeutics, Inc. (BOLT)
| Chiusura precedente | 0,7600 |
| Aperto | 0,7761 |
| Denaro | 0,5259 x 200 |
| Domanda | 0,7649 x 100 |
| Min-Max giorno | 0,7600 - 0,7761 |
| Intervallo di 52 settimane | 0,7340 - 1,8100 |
| Volume | |
| Media Volume | 238.720 |
| Capitalizzazione | 28,985M |
| Beta (mensile su 5 anni) | 1,05 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,6600 |
| Prossima data utili | 05 ago 2024 - 09 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 1,25 |
GlobeNewswireBolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023
REDWOOD CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company pioneering novel immuno-oncology therapeutics for the treatment of cancer, today announced that updated clinical data from its Phase 1/2 dose-escalation study of BDC-1001 will be presented in a mini-oral presentation at the European Society for Medical Oncology (ESMO) Congress 2023, being held in Madrid, Spain and virtually from October 20-24, 2023. BDC-10
- GlobeNewswire
Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers
BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in Phase 2 development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancersThe FDA granted BDC-1001 Orphan Drug Designation for the treatment of gastric cancer, including gastroesophageal junction cancer REDWOOD CITY, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, t
- GlobeNewswire
Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042
REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, announced today the issuance of the first and foundational patent covering BDC-3042. The U.S. Patent and Trademark Office (USPTO) issued U.S. Patent 11,753,474 titled “Anti-Dectin-2 Antibodies,” on September 12, 2023. “The issuance of this patent is an important milestone in protecting the comp
